Product apis-jak-stat

Home > products > apis> jak-stat

Catalog	name	Description	price
R-R-2325	G5-7 CAS No.939681-36-4	G5-7/CAS No.939681-36-4, an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study.	price>
R-R-2326	a7 nAchR-JAK2-STAT3 agonist 1 CAS No.2108714-20-9	α7 nAchR-JAK2-STAT3 agonist 1/CAS No.2108714-20-9 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC50 value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis.	price>
R-R-2327	(2R,5S)-Ritlecitinib CAS No.1792180-79-0	(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600)/CAS No.1792180-79-0 is a potent and selective JAK3 inhibitor (IC50=144.8 nM) extracted from patent US20150158864A1, example 68.	price>
R-R-2328	JAK-IN-14 CAS No.1973485-06-1	JAK-IN-14/CAS No.1973485-06-1 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16).	price>
R-R-2329	SD-1029 CAS No.118372-34-2	SD-1029/CAS No.118372-34-2 is a JAK2/STAT3 inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation.	price>
R-R-2330	SJ988497 CAS No.2595365-41-4	SJ988497/CAS No.2595365-41-4 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL).	price>
R-R-2331	Tofacitinib-d3 citrate CAS No.2701680-77-3	Tofacitinib-d3 (citrate)/CAS No.2701680-77-3 is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.	price>
R-R-2332	Ilginatinib maleate CAS No.1354799-87-3	Ilginatinib maleate (NS-018 maleate)/CAS No.1354799-87-3 is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).	price>
R-R-2333	Oclacitinib CAS No.1208319-26-9	Oclacitinib/CAS No.1208319-26-9 is a novel JAK inhibitor. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).	price>
R-R-2334	Pumecitinib CAS No.2401057-12-1	Pumecitinib/CAS No.2401057-12-1 is a Janus kinase (JAK) inhibitor with anti-inflammatory activity.	price>

...